ArticleVeterinary dermatology2026
Treatment of Canine Pemphigus Foliaceus, Pemphigus Vulgaris and Mucous Membrane Pemphigoid With Oclacitinib: A Retrospective Analysis of 21 Cases.
Article in Veterinary dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study was performed to retrospectively evaluate the efficacy of oclacitinib (OC) (Apoquel; Zoetis) as a treatment option for pemphigus foliaceus (PF), pemphigus vulgaris (PV) and mucous membrane pemphigoid (MMP).
objectiveTo determine if OC can reduce or replace the corticosteroid use in dogs with PF, PV and MMP. ANIMALS: There were no animal subjects. PROCEDURE: Multicentre retrospective study reviewing medical records from two institutions for dogs diagnosed with PF, PV or MMP and prescribed OC between 2014 and 2025.
resultsTwenty-one dogs diagnosed with PF, PV or MMP via histopathological results were included. OC alone was effective in eight of 18 PF dogs at a median dose of 0.65 mg/kg/day per os (range 0.5-1.9 mg/kg/day p.o.). Five dogs reached clinical remission, and three reached partial remission. One PV dog and the MMP dog each reached clinical remission with OC alone at 0.7 mg/kg/day and 0.24 mg/kg every other day, respectively. OC was a corticosteroid-sparing agent or adjunctive therapy in seven of 18 PF dogs at a median dose of 0.6 mg/kg/day (range 0.4-2.4 mg/kg/day). One PV dog reached partial remission at OC 1.9 mg/kg/day and prednisone 1.8 mg/kg/day yet died from pancreatitis. OC was ineffective in three of 18 PF dogs at a median dose of 1.0 mg/kg/day p.o. (range 0.9-1.2 mg/kg/day p.o.). Statistical significance was not analysed. CONCLUSIONS AND CLINICAL RELEVANCE: OC is an effective sole therapeutic agent or adjunctive therapy in a subset of dogs with PF, PV or MMP. The long-term safety of higher doses of OC is unknown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.